Whole-exome sequencing (WES) of samples from patients (pts) classified as exceptional responders (ER) vs poor responders (PO) to targeted therapies in pancreatic neuroendocrine tumours (pNETs).
Authors
Barriuso, JorgeLamarca, Angela
McNamara, Mairéad G
Manoharan, Prakash
Moghadam, Sharzad
Rogan, Jane
Hayes, A
Mansoor, Was
Hubner, Richard A
Valle, Juan W
Affiliation
The Christie NHS Foundation Trust (ENETS Centre of Excellence). Division of Molecular & Clinical Cancer Sciences, University of Manchester, ManchesterIssue Date
2017